Fortuna Health vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 39)
Fortuna Health logo

Fortuna Health

EmergingHealthcare

General

NYC YC "TurboTax for Medicaid" at $22M total ($18M a16z Series A Jul 2025) with AI + live navigators reducing member churn 15% addressing $50B administrative waste; 12-person team competing with Maximus for Medicaid enrollment technology.

AI VisibilityBeta
Overall Score
D39
Category Rank
#416 of 596
AI Consensus
81%
Trend
up
Per Platform
ChatGPT
41
Perplexity
35
Gemini
40

About

Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowitz (a16z) with BoxGroup, and a $4 million seed in November 2023 from YC, BoxGroup, and angel investors including founders of Zocdoc, PillPack, and Cityblock Health — providing Medicaid health plans, providers, and state governments with an AI-powered Medicaid navigation platform that pairs AI automation with live human navigators to guide beneficiaries through enrollment, coverage maintenance, and renewal workflows, reducing member churn by 15% and addressing the $50 billion in administrative waste that the US Medicaid system generates annually. Founded in 2023 by Cydney Kim, Nikita Singareddy, and Ben Wesner, Fortuna Health operates with a 12-person team and has been described as "TurboTax for Medicaid."

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

39
Overall Score
90
#416
Category Rank
#2
81
AI Consensus
83
up
Trend
up
41
ChatGPT
92
35
Perplexity
93
40
Gemini
89
34
Claude
96
38
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.